You are here: Industry Insights > Epidiolex

News List

Can CBD Help Curb COVID? Maybe, But More Study Needed drugs.com
January 24, 2022
Cannabidiol, a compound derived from marijuana, appears to show promise in blocking replication...
FDA Approves New Indication for Drug Containing Cannabis for Seizures in Rare Genetic Disease americanpharmaceuticalreview
August 10, 2020
The U.S. Food and Drug Administration (FDA) has approved Epidiolex (cannabidiol) [CBD] oral solution for the treatment of seizures associated with tuberous sclerosis complex (TSC) in patients one year of age and older.
GW Pharmaceuticals Appoints CCO contractpharma
April 15, 2019
GW Pharmaceuticals plc announced the appointment of Darren Cline as its new U.S. chief commercial officer...
After November rollout, GW Pharma says Epidiolex positioned for strong growth fiercepharma
March 06, 2019
GW Pharmaceuticals may be the first drugmaker to roll out a cannabis-based drug in the U.S., but it's unlikely to be the last—and that's why so many are keeping an eye on GW's Epidiolex launch.
GW Pharmaceuticals launches cannabis-based drug Epidiolex in US pharmaceutical-technology
November 06, 2018
UK-based GW Pharmaceuticals and its US division Greenwich Biosciences have launched an oral solution of cannabis-based drug Epidiolex in the US to treat seizures in Lennox-Gastaut syndrome (LGS) or Dravet syndrome patients aged two years and above.
GW Pharma’s Epidiolex nears US launch pharmatimes
September 29, 2018
GW Pharmaceuticals and its subsidiary Greenwich Biosciences are gearing up to launch Epidiolex in the US after drug enforcement officials re-classified...
FDA Approves Epidiolex drugs
June 26, 2018
The U.S. Food and Drug Administration today approved Epidiolex (cannabidiol) [CBD] oral solution for the treatment of seizures associated with two rare and severe forms of epilepsy
FDA greenlights GW's Epidiolex, the first U.S. drug made from marijuana fiercepharma
June 26, 2018
The FDA just approved Epidiolex, the GW Pharma seizure drug derived from cannabis, giving children with two rare and serious forms of epilepsy a new treatment...
GW’s Epidiolex takes a leap toward US approval pharmatimes
April 20, 2018
Shares in GW Pharma were given a boost after its cannabinoid Epidiolex took a giant leap towards US approval for treating seizures linked with Lennox-Gastaut (LGS) and Dravet syndromes.
EMA grants Orphan Drug Designation to GW Pharmaceuticals’ Epidiolex pharmaceutical-technology
March 31, 2017
The European Medicines Agency (EMA) has granted Orphan Drug Designation to UK-based GW Pharmaceuticals’ investigational product Epidiolex (cannabidiol or CBD) to treat Lennox-Gastaut Syndrome (LGS).